Palmoplantar pustulosishttps://en.wikipedia.org/wiki/Pustulosis_palmaris_et_plantaris
Palmoplantar pustulosis bụ ọrịa akpụkpọ anụ pustular na-adịghị ala ala (ya bụ, pustulosis ma ọ bụ pustular psoriasis) nke na-emetụta naanị aka na ụkwụ, a na-ahụ ya site na pustules intraepidermal juputara na neutrophils. Ojiji naanị sistemụ retinoids yana photochemotherapy nwere ike imeziwanye akara palmoplantar pustulosis.

○ Ọgwụgwọ
Acitretin oral dị irè maka ụdị psoriasis a.
#Acitretin
☆ AI Dermatology — Free Service
Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
  • N'okwu a, pompholyx nwekwara ike ịtụgharị ya n'ịhụhụ.
  • Ọ bụrụ na enweghị pustules, a pụkwara iwere eczema dịka nchọpụta dị iche.
References Palmoplantar Psoriasis 28846363 
NIH
Palmoplantar psoriasis bụ ụdị psoriasis nke na-emetụta akpụkpọ ahụ n'ala aka na ụkwụ gị. Ọ na-apụta dị ka akpụkpọ ahụ nwere nkụ, ọnya, ma ọ bụ ngwakọta nke ụdị abụọ ahụ.
Palmoplantar psoriasis is a variant of psoriasis that characteristically affects the skin of the palms and soles. It features hyperkeratotic, pustular, or mixed morphologies.
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).